Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.760
-0.100 (-2.06%)
At close: Feb 4, 2026, 4:00 PM EST
4.760
0.00 (0.00%)
After-hours: Feb 4, 2026, 4:10 PM EST
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $3.56M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $3.99M, down -58.26% year-over-year. In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%.
Revenue (ttm)
$3.99M
Revenue Growth
-58.26%
P/S Ratio
20.27
Revenue / Employee
$498,463
Employees
8
Market Cap
111.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 142.53M |
| MacroGenics | 127.63M |
| Verrica Pharmaceuticals | 30.83M |
| Korro Bio | 7.37M |
| Cardiff Oncology | 501.00K |
| Inovio Pharmaceuticals | 182.34K |
| Genelux | 8.00K |
COYA News
- 5 days ago - Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire
- 15 days ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire
- 27 days ago - Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
- 4 weeks ago - Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - Business Wire
- 6 weeks ago - Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire
- 2 months ago - Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 2 months ago - Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - Business Wire
- 3 months ago - Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update - Business Wire